Drugs / Live Combined Bifidobacterium
Live Combined Bifidobacterium
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT04017403 | Dec 2019 → Dec 2023 | avascular necrosis, lumbar disk disease, osteoarthritis, knee | RenJi Hospital | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Live Combined Bifidobacterium | “Participants (n = 220) will receive probiotics (Peifeikang, Live Combined Bifidobacterium, 210 mg per capsule, twice a day, four capsules each time” PMID 36841790 ↗ Feb 2023 |
| Known as | Bifidobacterium triple live capsule | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04017403 ↗ |
| Known as | Peifeikang | “Participants (n = 220) will receive probiotics (Peifeikang, Live Combined Bifidobacterium, 210 mg per capsule, twice a day, four capsules each time” PMID 36841790 ↗ Feb 2023 |
| Modality | Other / unclassified | “Participants (n = 220) will receive probiotics (Peifeikang, Live Combined Bifidobacterium, 210 mg per capsule, twice a day, four capsules each time” PMID 36841790 ↗ Feb 2023 |
| Route | Oral | “The drug is taken orally, 4 capsules at a time, 2 times a day.” NCT04017403 ↗ |